β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
Felipe C. Geyer(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Alan Mackay(Institute of Cancer Research), Kay Savage(Institute of Cancer Research), Mónica Arnedos, Magali Lacroix‐Triki(Université Paris-Saclay), Maryou B. Lambros(Institute of Cancer Research), Rachael Natrajan(Institute of Cancer Research)
Cited by 377
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k